PHOENIX, Sept. 22, 2011 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced that industry veteran Jack Bush has joined the company as Vice President, Marketing for the Healthcare Analytics business. Bush has spent the last quarter century working for many diverse pharmaceutical companies both large and small, global and domestic, where he has honed an understanding for what customers need most from their data.
"Jack's been in our customers' shoes for a long time and is well attuned to how they use data and how it can improve the bottom line performance of their brands," said Bob Jansen, President & Chief Commercial Officer, Healthcare Analytics, Wolters Kluwer Pharma Solutions. "He will be instrumental in providing the product leadership and market direction for our current product lines and all new product initiatives."
In this newly created role, Jack is responsible for all aspects of marketing strategy and management for the healthcare analytics business, including marketing communications, product forecasting, sales support and government affairs. He reports directly to Bob Jansen in Phoenix.
"As a long-time Pharma Solutions client, I know first hand the tremendous value of our data and I plan to illuminate that value to the marketplace," said Jack Bush, Vice President, Marketing, Healthcare Analytics, Wolters Kluwer Pharma Solutions. "My goal is to help show customers how to turn data into meaningful and actionable findings that can optimize revenue and brand performance."
Prior to joining Pharma Solutions, Bush held several senior management roles in pharmaceutical companies including Alcon, GlaxoSmithKline, Merck, Roche, and most recently Xanodyne Pharmaceuticals. He has performed global pharmaceutical brand management responsibilities, and brings extensive background in primary and secondary market research and database management. In addition, he has served as a senior level consultant providing services such as marketing communications, strategic planning, business development, competitive intelligence and product forecasting.
Bush holds a B.A. from Indianapolis University; a B.S. from Indiana University; and an M.A./M.B.A. from Indianapolis University.
For more information, visit the company's website at www.wolterskluwerpharma.com.
About Wolters Kluwer Pharma Solutions
Wolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.
The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2010 annual revenues of euro 3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
SOURCE Wolters Kluwer Pharma Solutions